vs
Caesarstone Ltd.（CSTE）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Caesarstone Ltd.的1.3倍（$127.1M vs $94.4M），再鼎医药自由现金流更多（$-26.7M vs $-47.1M），过去两年再鼎医药的营收复合增速更高（20.8% vs -57.8%）
凯撒斯通有限公司成立于1987年，总部位于以色列，是一家上市建材企业，主要生产销售石英、陶瓷、矿物及融合工艺饰面材料，产品广泛应用于厨房台面、化妆台面板、墙面装饰、室内地板及各类整体室内设计项目，目前在美国纳斯达克上市。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
CSTE vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.3倍
$94.4M
自由现金流更多
ZLAB
多$20.4M
$-47.1M
两年增速更快
ZLAB
近两年复合增速
-57.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.4M | $127.1M |
| 净利润 | $-87.9M | — |
| 毛利率 | 15.5% | 51.0% |
| 营业利润率 | -87.2% | -54.6% |
| 净利率 | -93.1% | — |
| 营收同比 | — | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-2.55 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSTEZLAB
| Q4 25 | $94.4M | $127.1M | ||
| Q3 25 | $345.4M | $115.4M | ||
| Q2 25 | $237.7M | $109.1M | ||
| Q1 25 | — | $105.7M | ||
| Q4 24 | — | $108.5M | ||
| Q3 24 | $436.7M | $101.8M | ||
| Q2 24 | $294.3M | $100.1M | ||
| Q1 24 | $150.6M | $87.1M |
净利润CSTEZLAB
| Q4 25 | $-87.9M | — | ||
| Q3 25 | $-18.5M | $-36.0M | ||
| Q2 25 | $-14.3M | $-40.7M | ||
| Q1 25 | — | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-57.4M | $-41.7M | ||
| Q2 24 | $-56.6M | $-80.3M | ||
| Q1 24 | $-3.9M | $-53.5M |
毛利率CSTEZLAB
| Q4 25 | 15.5% | 51.0% | ||
| Q3 25 | 22.5% | 59.5% | ||
| Q2 25 | 23.7% | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | 15.7% | 64.1% | ||
| Q2 24 | 14.1% | 64.9% | ||
| Q1 24 | 19.7% | 61.4% |
营业利润率CSTEZLAB
| Q4 25 | -87.2% | -54.6% | ||
| Q3 25 | -5.5% | -42.3% | ||
| Q2 25 | -6.2% | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | -12.6% | -66.6% | ||
| Q2 24 | -18.0% | -76.0% | ||
| Q1 24 | -3.9% | -80.7% |
净利率CSTEZLAB
| Q4 25 | -93.1% | — | ||
| Q3 25 | -5.4% | -31.2% | ||
| Q2 25 | -6.0% | -37.3% | ||
| Q1 25 | — | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -13.1% | -40.9% | ||
| Q2 24 | -19.2% | -80.2% | ||
| Q1 24 | -2.6% | -61.4% |
每股收益（稀释后）CSTEZLAB
| Q4 25 | $-2.55 | $-0.05 | ||
| Q3 25 | $-0.54 | $-0.03 | ||
| Q2 25 | $-0.41 | $-0.04 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | $-1.67 | $-0.04 | ||
| Q2 24 | $-1.64 | $-0.08 | ||
| Q1 24 | $-0.11 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $58.4M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $139.2M | $715.5M |
| 总资产 | $398.4M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSTEZLAB
| Q4 25 | $58.4M | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
总债务CSTEZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-12.6M | — |
股东权益CSTEZLAB
| Q4 25 | $139.2M | $715.5M | ||
| Q3 25 | $271.6M | $759.9M | ||
| Q2 25 | $271.6M | $791.7M | ||
| Q1 25 | — | $810.8M | ||
| Q4 24 | — | $840.9M | ||
| Q3 24 | $315.1M | $667.7M | ||
| Q2 24 | $315.1M | $704.2M | ||
| Q1 24 | $315.1M | $762.2M |
总资产CSTEZLAB
| Q4 25 | $398.4M | $1.2B | ||
| Q3 25 | $549.0M | $1.2B | ||
| Q2 25 | $549.0M | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $579.9M | $985.3M | ||
| Q2 24 | $579.9M | $987.4M | ||
| Q1 24 | $579.9M | $988.4M |
负债/权益比CSTEZLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-38.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-47.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | -49.8% | -21.0% |
| 资本支出强度资本支出/营收 | 9.6% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $38.6M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流CSTEZLAB
| Q4 25 | $-38.0M | $-26.0M | ||
| Q3 25 | $35.0M | $-32.0M | ||
| Q2 25 | $18.7M | $-31.0M | ||
| Q1 25 | — | $-61.7M | ||
| Q4 24 | — | $-55.8M | ||
| Q3 24 | $53.3M | $-26.8M | ||
| Q2 24 | $25.1M | $-42.2M | ||
| Q1 24 | $7.9M | $-90.1M |
自由现金流CSTEZLAB
| Q4 25 | $-47.1M | $-26.7M | ||
| Q3 25 | $26.7M | $-35.0M | ||
| Q2 25 | $14.3M | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | $44.6M | $-28.2M | ||
| Q2 24 | $20.7M | $-42.9M | ||
| Q1 24 | $5.0M | $-91.1M |
自由现金流率CSTEZLAB
| Q4 25 | -49.8% | -21.0% | ||
| Q3 25 | 7.7% | -30.4% | ||
| Q2 25 | 6.0% | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | 10.2% | -27.7% | ||
| Q2 24 | 7.0% | -42.9% | ||
| Q1 24 | 3.3% | -104.5% |
资本支出强度CSTEZLAB
| Q4 25 | 9.6% | 0.5% | ||
| Q3 25 | 2.4% | 2.6% | ||
| Q2 25 | 1.8% | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | 2.0% | 1.3% | ||
| Q2 24 | 1.5% | 0.7% | ||
| Q1 24 | 1.9% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSTE
| America's | $53.0M | 56% |
| USA | $41.4M | 44% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
